Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Regulus doubles on single-dose hepatitis C data

This article was originally published in Scrip

Executive Summary

It's far too early to know whether Regulus Therapeutics has a therapy that could compete with the new crop of blockbuster drugs that treat the hepatitis C virus (HCV), but the company's stock price doubled on 22 October based on impressive single-dose results from an ongoing Phase I clinical trial for RG-101.

Advertisement

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC026698

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel